Drug Resistance, Neoplasm
"Drug Resistance, Neoplasm" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Resistance or diminished response of a neoplasm to an antineoplastic agent in humans, animals, or cell or tissue cultures.
Concept/Terms
Drug Resistance, Neoplasm- Drug Resistance, Neoplasm
- Antineoplastic Drug Resistance
- Drug Resistance, Antineoplastic
- Resistance, Antineoplastic Drug
- Resistance, Antineoplastic Agent
- Antineoplastic Agent Resistance
- Neoplasm Drug Resistance
Below are MeSH descriptors whose meaning is more general than "Drug Resistance, Neoplasm".
Below are MeSH descriptors whose meaning is more specific than "Drug Resistance, Neoplasm".
This graph shows the total number of publications written about "Drug Resistance, Neoplasm" by people in Harvard Catalyst Profiles by year, and whether "Drug Resistance, Neoplasm" was a major or minor topic of these publication.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1995 | 1 | 4 | 5 |
| 1996 | 1 | 3 | 4 |
| 1997 | 1 | 2 | 3 |
| 1998 | 5 | 5 | 10 |
| 1999 | 0 | 9 | 9 |
| 2000 | 4 | 7 | 11 |
| 2001 | 2 | 16 | 18 |
| 2002 | 10 | 19 | 29 |
| 2003 | 17 | 23 | 40 |
| 2004 | 14 | 28 | 42 |
| 2005 | 17 | 37 | 54 |
| 2006 | 16 | 40 | 56 |
| 2007 | 28 | 52 | 80 |
| 2008 | 35 | 41 | 76 |
| 2009 | 37 | 59 | 96 |
| 2010 | 49 | 55 | 104 |
| 2011 | 47 | 56 | 103 |
| 2012 | 46 | 71 | 117 |
| 2013 | 62 | 78 | 140 |
| 2014 | 84 | 94 | 178 |
| 2015 | 111 | 79 | 190 |
| 2016 | 109 | 97 | 206 |
| 2017 | 87 | 113 | 200 |
| 2018 | 100 | 106 | 206 |
| 2019 | 89 | 89 | 178 |
| 2020 | 45 | 44 | 89 |
| 2021 | 5 | 3 | 8 |
Below are the most recent publications written about "Drug Resistance, Neoplasm" by people in Profiles.
-
Single-cell transcriptional changes associated with drug tolerance and response to combination therapies in cancer. Nat Commun. 2021 03 12; 12(1):1628.
-
Multimodal pooled Perturb-CITE-seq screens in patient models define mechanisms of cancer immune evasion. Nat Genet. 2021 03; 53(3):332-341.
-
Treatment of relapsed and refractory multiple myeloma: recommendations from the International Myeloma Working Group. Lancet Oncol. 2021 03; 22(3):e105-e118.
-
Idecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma. N Engl J Med. 2021 02 25; 384(8):705-716.
-
Enfortumab Vedotin in Previously Treated Advanced Urothelial Carcinoma. N Engl J Med. 2021 03 25; 384(12):1125-1135.
-
Integrated Genomics Identifies miR-181/TFAM Pathway as a Critical Driver of Drug Resistance in Melanoma. Int J Mol Sci. 2021 Feb 11; 22(4).
-
Biallelic loss of BCMA as a resistance mechanism to CAR T cell therapy in a patient with multiple myeloma. Nat Commun. 2021 02 08; 12(1):868.
-
Imaging dynamic mTORC1 pathway activity in vivo reveals marked shifts that support time-specific inhibitor therapy in AML. Nat Commun. 2021 01 11; 12(1):245.
-
Changes in Bcl-2 members after ibrutinib or venetoclax uncover functional hierarchy in determining resistance to venetoclax in CLL. Blood. 2020 12 17; 136(25):2918-2926.
-
Serine-70 phosphorylated Bcl-2 prevents oxidative stress-induced DNA damage by modulating the mitochondrial redox metabolism. Nucleic Acids Res. 2020 12 16; 48(22):12727-12745.